Monitoring the effectiveness of risk minimisation in patients treated with pioglitazone-containing products

Documents

Study protocol

Initial protocol

D4 b Final Study Protocol vFinal

Updated protocol

D4 b Final Study Protocol vFinal_Amendment 07 11 2012

First published: 22/02/2024

Study results

Study results

D5.a Interim report on the study results

D5b D1 D2 Final report on study results_final version

Study report

Study report

D5.a Interim report on the study results (Appendix 2)

Other information

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

2012-0010-DoI HT Sorensen-SDPP-2765

Composition of steering group and observers

Steering Committee_Pioglitazone

Signed code of conduct

2012-0010-DoC CoC-SDPP-2765

Signed code of conduct checklist

2012-0010-Checklist CoC-SDPP-2765

Signed checklist for study protocols

2012-0010-Checklist Study Protocol-SDPP-2765